Literature DB >> 21779920

The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity.

Thomas Lehnert1, Margit Weisser, Holger Till, Udo Rolle.   

Abstract

OBJECTIVES: To assess whether conservative treatment of pediatric patients with neurogenic detrusor overactivity (NDO) results in lower bladder pressure and increased expected bladder volume (EBV), we investigated the clinical and urodynamic effects of long-term intravesical oxybutynin instillation compared with a standard treatment of oral anticholinergic medication in patients with clean intermittent catheterization (CIC).
METHODS: A retrospective study was performed including 21 patients suffering from myelomeningocele and NDO. Initially, all patients were treated with oral anticholinergics and CIC. Ten of the 21 patients showed a sufficient response to the treatment and were included in group I (anticholinergics and CIC). The other 11 patients responded poorly to the initial treatment or developed side effects to oral medication. These patients were included in group II and treated with intravesical oxybutynin and CIC. The two groups were compared using clinical, sonographic and urodynamic examinations performed prior to starting treatment and repeated on an annual basis. Changes from baseline were analyzed with the Mann-Whitney U test.
RESULTS: Ten patients in group I and 11 in group II were investigated. Two of the 11 patients in group II stopped the treatment. The mean starting age was 8.1 (± 6.6) years in group I and 12.5 (± 4.5) years in group II. The mean follow-up time was 7.1 (± 5.5) years in group I and 3.6 (± 1.8) years in group II. Bladder capacity increased from 173 (± 99) to 371 (± 115) ml in group I and from 245 (± 133) to 370 (± 156) ml in group II. Six of the 10 patients in group I and 6/9 patients in group II reached normal EBV. Three of the 10 subjects in group I and 6/9 in group II had bladder compliance values >10 ml/cm H(2)O. At final follow-up, the overall rate of urinary tract infections was equal. Social continence was achieved in 6/10 in group I and 7/9 in group II. Altogether, 19/21 patients responded to conservative management.
CONCLUSIONS: In children with NDO, conservative medical treatment combined with CIC is feasible and provides an improved pattern of bladder function, which could help avoid bladder surgery.

Entities:  

Mesh:

Year:  2011        PMID: 21779920     DOI: 10.1007/s11255-011-0030-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  34 in total

Review 1.  The management of the myelodysplastic child: a paradigm shift.

Authors:  S B Bauer
Journal:  BJU Int       Date:  2003-10       Impact factor: 5.588

2.  The pharmacokinetics of intravesical and oral oxybutynin chloride.

Authors:  C A Massad; B A Kogan; F E Trigo-Rocha
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

3.  Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.

Authors:  Kari Lehtoranta; Hanna Tainio; Eeva Lukkari-Lax; Tiina Hakonen; Teuvo L J Tammela
Journal:  Scand J Urol Nephrol       Date:  2002-02

4.  Early start to therapy preserves kidney function in spina bifida patients.

Authors:  Pieter Dik; Aart J Klijn; Jan D van Gool; Catherine C E de Jong-de Vos van Steenwijk; Tom P V M de Jong
Journal:  Eur Urol       Date:  2006-01-19       Impact factor: 20.096

5.  Detrusor overactivity in spina bifida: how long does it need to be treated?

Authors:  Elisabeth Ab; Pieter Dik; Aart J Klijn; Jan D van Gool; Tom P V M de Jong
Journal:  Neurourol Urodyn       Date:  2004       Impact factor: 2.696

6.  Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.

Authors:  C Do Ngoc Thanh; G Audry; V Forin
Journal:  J Pediatr Urol       Date:  2009-07-03       Impact factor: 1.830

7.  Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.

Authors:  P Amark; G Bussman; S Eksborg
Journal:  Eur Urol       Date:  1998-08       Impact factor: 20.096

8.  Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia.

Authors:  Marcus Riccabona; Mark Koen; Monica Schindler; Beckers Goedele; Armin Pycha; Lukas Lusuardi; Stuart B Bauer
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  Treatment with modified intravesical oxybutynin chloride for neurogenic bladder in children.

Authors:  Atsushi Hayashi; Motoaki Saito; Shin-ichi Okada; Takuya Hanada; Takeshi Watanabe; Keisuke Satoh; Susumu Kanzaki
Journal:  J Pediatr Urol       Date:  2007-08-02       Impact factor: 1.830

10.  Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.

Authors:  Helmut Madersbacher; Gerd Mürtz; Schahnaz Alloussi; Burghard Domurath; Thomas Henne; Iris Körner; Andreas Niedeggen; Joseph Nounla; Jürgen Pannek; Heinrich Schulte-Baukloh; Daniela Schultz-Lampel; Paul Bock; Gerhard Strugala
Journal:  BJU Int       Date:  2008-10-24       Impact factor: 5.588

View more
  5 in total

1.  Success rates for learning intermittent self-catheterisation according to age and gender.

Authors:  Brian A Parsons; Anita Narshi; Marcus J Drake
Journal:  Int Urol Nephrol       Date:  2012-02-18       Impact factor: 2.370

2.  Functional electrical stimulation for management of urinary incontinence in children with myelomeningocele: a randomized trial.

Authors:  Abdol-Mohammad Kajbafzadeh; Lida Sharifi-Rad; Seyedeh Sanam Ladi Seyedian; Ahmad Masoumi
Journal:  Pediatr Surg Int       Date:  2014-04-17       Impact factor: 1.827

3.  Neurogenic bladder findings in patients with Congenital Zika Syndrome: A novel condition.

Authors:  Lucia Maria Costa Monteiro; Glaura Nisya de Oliveira Cruz; Juliana Marin Fontes; Tania Regina Dias Saad Salles; Marcia Cristina Bastos Boechat; Ana Carolina Monteiro; Maria Elizabeth Lopes Moreira
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

Review 4.  Preventing kidney injury in children with neurogenic bladder dysfunction.

Authors:  Faezeh Javadi Larijani; Mastaneh Moghtaderi; Nilofar Hajizadeh; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2013-12

5.  Study of serum and urinary markers of the renin-angiotensin-aldosterone system in myelomeningocele patients with renal injury detected by DMSA.

Authors:  Cássia Maria Carvalho Abrantes do Amaral; Dulce Elena Casarini; Maria Cristina Andrade; Marcela Leal da Cruz; Antônio Macedo
Journal:  Int Braz J Urol       Date:  2020 Sep-Oct       Impact factor: 3.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.